NewsRx

Search our medical news database

Coronary Stents

Company sells $42M in stent systems in 10 days

Published in Drug Week, April 23rd, 2004

Boston Scientific Corporation (BSX) announced preliminary information related to U.S. sales of its Taxus Express paclitaxel-eluting coronary stent system.

The company received approval from the U.S. Food and Drug Administration on March 4 to market the Taxus system in the United States, and it recorded its first sale on March 8.

Preliminary net sales from March 8 through March 19 (10 selling days) were approximately $42 million. At its February 23rd analyst meeting, the company estimated Taxus system sales of between $52 million and $75 million for the period of March 1 through March 31 (23 selling days).

The company estimates the...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook